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Abstract 
Obscurin (720-900 kD) is a giant sarcomeric signaling protein that is the only known link 
between the cytoskeleton and the surrounding membrane structure. Mutations to obscurin 
and to obscurin binding partners have been linked to human muscle diseases such as 
hypertrophic cardiomyopathies and muscular dystrophy. These diseases likely occur due 
to the abrogation of specific molecular interactions necessary for suitable function. To 
more fully understand how specific mutations lead to disease, here we solve the high-
resolution structure of obscurin Ig58. The literature shows that an Arg8Gln mutation to 
the Ig58 domain of obscurin is associated with hypertrophic cardiomyopathy (HCM).  
Chemical shift changes of this mutation and MD simulations suggest that this mutation 
disrupts a large charge-charge surface of Ig58, perturbing the titin-binding interface.  
 
 
 
 
 
 
 
 
 
 
 
 
	   
6	  
 
Introduction 
 Muscular motion, at its most basic level, results from the motions of multiple 
connected proteins, each with one or many unique functions, within the cell. In order to 
understand these molecular motions, we can study each of these unique proteins and 
investigate their role in force generation, stretch resistance, and stretch signaling in 
muscle. This will provide insight into why certain mutations lead to a breakdown of 
muscle cells and a pathological loss of the components that underlie controlled muscle 
motion. Muscle proteins are exquisitely arranged within the myofibril, and make up the 
macromolecular structure called the sarcomere. Sarcomeres are the most basic unit of 
contraction in striated muscle1. Figure 1 shows a histological slide of striated muscle 
under a microscope with the two main components of the sarcomere, Actin and Myosin, 
appearing as light and dark horizontal lines, respectively (Figure 1). These two long 
filamentous fibers that slide past each other during muscular contraction and relaxation2,3. 
In order to understand where different protein components of the sarcomere localize, it is 
necessary to recognize the specific terminology used for the arrangement of the 
sarcomere: I-band, A-band, Z-lines, and M-line. The isotropic band, or I-band, is the area 
of actin polymers that have no overlap with myosin3. The length of the I-band is subject 
to change as the sarcomere shortens, resulting from the actin and myosin filaments 
sliding past each other upon  
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Figure 1. Schematic of the sarcomere directly aligned with a histological slide of 
striated muscle4.  
 
contraction, thus producing a shortened area of actin filaments without myosin overlap. 
The darker anisotropic band, or A-band, refers to the entire length of myosin filaments 
and does not change in length upon contraction3. The length of a single sarcomere is 
defined as the distance between two Z-lines, which correspond to the dark vertical bands 
of the histological slide in Figure 1. The Z-line of striated muscle is also the point where 
the pointed termi of actin polymers are anchored5. The M-line is defined as the middle of 
the sarcomere and refers to the cross connecting of the two bipolar chains of a single 
thick filament6.  
 F-actin, referred to as the thin filament, is a double helix of actin monomers and is 
roughly 40 Å in diameter but is as much as several microns in length. Two important thin 
filament associated proteins in striated muscle are the globular protein troponin and the 
filamentous protein tropomyosin shown in pink and blue of Figure 2A, respectively. For 
every helical turn of actin, there are two troponin complexes lying in direct contact with 
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both actin and tropomyosin. Tropomyosin, twists around the actin double helix and 
sterically blocks the myosin binding sites in the absence of Ca2+ ion2,1 (Figure 2A).  
 
 
 
 
 
 
 
Figure 2. Schematic of A) actin filament wrapped by tropomyosin with troponin 
B) single myosin filament including light and heavy chain regions C) myosin 
filament bundle. Figure adapted from Hooper et al2. 
 
 Myosin, often referred to as the thick filament of about 110 Angstroms in 
diameter, is composed of three pairs of molecules1 2 3. The first pair is known as the 
heavy chain, which wind together to form a coiled-coil tail, both shown in Figure 2B as 
two globular heads and thin long tails, respectively. The other two are known as the 
essential light chain and the regulatory chain, which combined with the other end of the 
heavy chain form one of the combined molecule’s two globular heads2. All of the 
components of the thin and thick filament are necessary for contraction to occur. 
 Muscle contraction takes place when calcium ions are released from the 
sarcoplasmic reticulum and are able to move in to the sarcomere and bind to troponin1,7. 
This calcium binding alters the structure of troponin molecules and causes them to move 
A B C 
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the helical tropomyosin chain they are attached to, revealing previously covered myosin-
binding sites on the actin surface1,7. The myosin head binds and hydrolyzes ATP at its 
globular head region. This hydrolysis then initiates a conformational change where the 
myosin head is then 'cocked'1,7.  This complex then binds to the actin strand.  After 
binding to actin, the myosin head produces the power stroke, where the head repositions 
to its original orientation and the filaments slide past each other1,7.  ADP then leaves the 
Myosin head and ATP is free to enter.  This event results in myosin detaching from actin, 
thus allowing the contractile apparatus and muscle cell to relax. The cycle can then repeat 
as long as tropomyosin does not occlude the myosin binding site on actin. Large-scale 
motions that result from muscular contractions are therefore, at their most basic level, the 
direct result of microscopic molecular movements.  
  The sliding filament hypothesis7 is almost always presented in textbooks 
exclusively for its properties of the generation of force involved in the contraction of 
muscle and presents several important protein structures that work in tandem to make this 
possible. A complete understanding of the sarcomere however, is much more involved. 
The main aim of this research is to investigate the equally important ability of muscle to 
not only contract, but to expand. However, there is a general lack of understanding about 
the properties of striated muscle for regulated expansion, and resistance to expansion. 
While there are likely many proteins involved in this process, there is a limited 
understanding of what players are involved. Probably the most well understood 
component of the regulation of muscle expansion is the giant filamentous protein titin 
and secondly obscurin. Both obscurin and titin are represented below in Figure 3, in their 
likely locations based on known binding targets. 
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Figure 3. Schematic of the sarcomere with giant muscle proteins highlighted.  
Obscurin, in blue, links titin (red) to the surrounding SR membrane and T-tubule 
structure in striated muscle. Figure from Meyer and Wright8. 
 
 Full length titin, is about 2993 kD with a pI of 6.359, is expressed in multiple 
isoforms, which vary in both length and strength, and is necessary for proper myocyte 
structure and function. Titin is made up of over 300 individual Ig-like folds, arranged in 
tandem and interspersed with occasional enzymatically active regions or other signaling 
motifs10,11,12 (Figure 4A). The protein in total resembles a long rope or chain and has been 
referred to as the “molecular ruler” of the sarcomere. Titin is a stretch sensor that 
regulates the length of the sarcomere10,11. While each individual domain is relatively 
immobile, the linkers between the domains are dynamic. Thus, titin can form many 
different conformations, much like a section of chain links can form many different kinds 
of shapes7. Titin, with its N and C terminal binding to the Z-band and M-band 
respectively, becomes elongated when the muscle stretches7 (Figure 4B). Titin therefore 
acts like an entalpic-entropic spring7.  As it is gradually elongated, individual titin Ig-like 
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domains straighten out, relative to each other.  This action breaks inter-Ig noncovalent 
forces, and this produces an enthalpic component to stretching.  Additionally, as titin 
stretches out it can conform to fewer and fewer conformations, and thus has a lower 
amount of entropy in the stretched form.  These two basic forces allow titin to gradually 
resist more and more force the further it is stretched, thus giving titin a bungee-cord like 
property to resist physical manipulations. Titin is extensively cross-linked at both the Z-
disk and M-band.  The interactions with proteins in these areas such as a-actin, MyBP-C, 
and obscurin not only generate the cytoskeletal architecture that the sarcomere relies on, 
but also provides malleable and dynamic protein mesh that can both resist and sense 
physical stretching forces. 
 
 
Figure 4. A) Schematic of titin in the sarcomere with domains and binding 
partners highlighted for regions near the M-band and Z-line. B) Sequence of 
stretching showing titin’s spring-like properties. Figure adapted from Granzier et 
al7. 
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 Similar in structure to titin is the protein obscurin. The structural similarity 
between the two suggests that they may also share a functional similarity. Obscurin is the 
most recently discovered giant protein involved in muscle contraction and was first 
identified as a ligand of the Z-disk titin domains Z9 and Z1012. Full length obscurin is 
roughly 720 kD and is known to play an important role in skeletal and cardiac muscle 
assembly12. The human isoform-a of obscurin has a pI of 5.549. While titin runs 
longitudinally through muscle cells, obscurin localization is more complicated.  Obscurin 
intercalates through the sarcomere in an apparently random pattern, and links the 
sarcomere to the surrounding membrane structures in muscle cells13,14.  In recent 
findings, obscurin has also been found in a diffuse pattern in non-muscle cell types15 
however, it is currently unclear why obscurin expresses in these other cells, what it might 
bind to, or what is its true subcellular distribution. Obscurin knockout and knockdown 
studies in mice show myocytes with poorly organized M and A bands of the sarcomere, 
poor sarcomere organization, altered muscle development, and generalized muscle 
weakening13,16. Obscurin is also a highly modular giant muscle protein and contains more 
than 60 Ig-like and FnIII-like domains, kinase signaling regions, calmodulin binding 
sites, and a RhoGEF signalling domain, among others. These domains and binding 
targets are highlighted in Figure 5.  
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Figure 5. Representation of the domains and target binding proteins of obscurin. 
Ig58/59 circled in red above, is the titin binding site on Ig582. A mutation in Ig58 
(Arg4344Gln, here referred to as Arg8Gln) is the only known mutation in obscurin 
that is directly related to human disease3. 
 
Most obscurin targets bind to discrete domains of obscurin, and are either other proteins 
involved in the structural organization of the sarcomere or are signaling proteins, which 
are freely diffuse13,17,18. The protein ankyrin, for example, aids in the functionality of the 
sarcomere through its interaction with obscurin. This interaction, along with titin, is 
thought to connect the contractile apparatus to the sarcoplasmic reticulum13,17,19. 
 The Ig58/59 tandem domains of obscurin bind to the ZIg9/10 tandem domains of 
titin, most likely at the Z-line12,20. Young, et al. proved that both obscurin and both titin 
domains must be present in order for binding to occur. This was demonstrated through 
Y2H and binding assay experiments and also suggested through isothermal calorimetric 
(ITC) experiments, although this group does not present the ITC data12. A population 
genetics study showed that a patient populace with hypertrophic cardiomyopathy (HCM) 
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also had a genetic variation that coded for a mutant variant of obscurin Ig58. This single 
amino acid mutation of Arg4333Gln is thought to be enough to disrupt obscurin-titin 
binding of these four domains completely, suggesting that this mutation may be 
responsible for the disease at which point we can only speculate over the reasons why10. 
HCM is characterized by a swelling or hypertrophy of the left ventricle due to enlarged 
myofibrils. This swelling obstructs the appropriate flow of blood in that the left ventricle 
does not achieve optimal preload volume and thus fails to deliver an adequate stroke 
volume of oxygenated blood to the rest of the body21. This disease manifests itself in a 
variety of symptoms including, but not limited to, arrhythmias and premature death20. 
HCM is also the most common cause of sudden cardiac death in adolescents22. Therefore, 
in order better understand the specific binding interactions between Ig58/59 and ZIg9/10 
and the role of this connection in the function of the cytoskeleton, we used both high and 
low resolution techniques to probe the structure of these domains, particularly Ig58. The 
high and low-resolution techniques used are X-ray crystallography, nuclear magnetic 
resonance spectroscopy (NMR), and small angle neutron scattering (SAXS). The 
information gathered can afford us information that has implications to pathologies like 
HCM.  
 The two common biophysical techniques used to solve the high-resolution 
structure of a protein or large molecule are nuclear magnetic resonance spectroscopy 
(NMR) and X-ray crystallography.  
 Like many other types of molecules, such as salts, proteins can be prompted to 
form crystals. The most commonly used method of protein crystallization is the hanging 
drop technique. In this technique, protein crystals form as vapor is displaced in a hanging 
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droplet of solution. Individual crystals can then be shot by an X-ray source with 
diffracted rays collected in a dot pattern, rotating the mounted crystal as the diffraction is 
collected. The position and intensity of the dots, within this pattern, contains information 
about the space group, and with the aid of mathematical interpretations, the electron 
density within the space group. In this type of data collection, phase information is lost. 
The loss of the phase is a fundamental limitation, which is ultimately related to the nature 
of the measurement and is due to a quantum mechanical phenomenon related to the wave 
particle duality of matter23,24. Techniques like molecular replacement, where the phases 
of a known structure are applied to the experimental data, can in an iterative technique, 
be used to obtain the phases of all the reflections. Once the phases are known Fourier 
transformation, sometimes called “the frequency domain representation of the original 
signal,” can be used to back-calculate the electron density of the protein within the 
crystal23,24. After obtaining three-dimensional data the protein molecule within the 
crystalline lattice can be fitted into the resulting electron density.  
 While obtaining a high-resolution structure through X-ray crystallography 
requires a solid protein crystal, NMR spectroscopy is performed on protein in solution. 
Nuclear magnetic resonance spectroscopy relies on the magnetic properties of isotopic 
atoms, which can absorb and re-emit electromagnetic radiation applied by a strong 
magnetic field25,26. The nuclei of the isotopic atoms are sent into discrete spin states by 
the applied magnetic field (Figure 6).  
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Figure 6. Green sphere, representing magnetic nucleus can be sent into a 
discrete spin state with angular momentum ω with the application of a strong 
magnetic field in the direction of the Z-axis27.  
 
These nuclear spin states have discrete angular momentums, which are manifested as 
specific peaks in an NMR spectrum.  Protein NMR experiments can assign individual 
peaks in an NMR spectrum to specific atoms within the protein, thus allowing sequence-
specific assignments of the atoms within the protein25,26.  Through-space NMR 
experiments can then be conducted to measure how close the nuclei are to each other.  
The compilation of all of the data collected from these experiments gives rise to an 
atomic-scale, high-resolution solution model. Similar to NMR spectroscopy, low-
resolution SAXS is performed on a protein in solution. 
 Low resolution SAXS data is collected from a special instrument that elastically 
scatters X-rays into the sample at low angles, a technique called small angle X-ray 
scattering (SAXS). The low angle range gives information about the shape and size of 
macromolecules, characteristic distances of partially order materials, and other important 
information28. Data can then analyzed using the program SASSIE, which analyzes data 
collected from fundamentally disordered biological molecules and can predict basic 
molecular parameters using experimental scattering restraints. 
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Experimental 
Purification 
 The GenBank protein database resource was used to identify the DNA sequence 
encoding human obscurin-a, accession number CAC44768.1. This sequence was then 
used to identify residues 4336-4428 of human obscurin-a as the predicted domain 
sequence of Ig2 via homology modeling with the program Phyre. This sequence was in 
accordance with the sequence determined by Kontrogianni-Konstantopoulos, et al. The 
codon optimized synthetic synthesis of the gene was ordered and obtained, with five 
additional residues added to the ends of the sequence in an attempt to ensure that the 
complete domain would be obtained. Extra residues were added due to a small amount of 
uncertainty in the exact size of the domain. This product was subsequently digested and 
ligated into the Ndel and Xhol restriction sites of the pET24a vector (Novagen). 
BL21(DE3) E. coli containing the Ig2 vector were grown in 5 L of 15N or 15N, 13C MOPS 
minimal media containing 30 mg/L kanamycin29. 15NH4 and 13C glucose was obtained 
from Cambridge Isotopes, Andover, MA. Cells were grown to an OD_600 of 0.6-0.8 and 
expression was induced with 1 mM IPTG for 4 h. Cells were then pelleted by 
centrifugation and stored at −80°C. For purification, cells were thawed and resuspended 
in 25 mL of 50 mM Sodium Phosphate (pH 8.0) with 300 mM NaCl and 10 mM 
imidazole. Cells were lysed by sonication and cellular debris was removed by 
centrifugation at 15,000 rpm. Purification of Ig58 was performed using a Ni-NTA nickel 
resin packed gravity column equilibrated with 50 mL of 50 mM Sodium Phosphate (pH 
8.0) with 300 mM NaCl and 100 mM imidazole. Using a 10 mM to 500 mM gradient of 
imidizole, Ig58 eluted into one fraction after the 500 mM imidazole elution step. 
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Fractions were analyzed by 10% Tris-Tricine SDS-PAGE gels stained with Coomassie 
Blue. The elution fraction was then concentrated down to 500 µl using an 5,000 MWCO 
Spin-X-UF Corning concentrator, and run over a G75 resin packed size-exclusion, 
gravity column, equilibrated with two column volumes of 20 mM Tris pH 7.5 and 50 mM 
NaCl, over a period of six hours. Protein eluted at fraction 30, consistent with other Ig 
domains. The protein was then concentrated to >1.5 mM as quantified by absorbance 
(ε280 = 11,620 M−1 cm−1) using a 5,000 MWCO Spin-X-UF Corning concentrator. 
X-ray: 
Ig58 protein was concentrated to 10.5-11.3 mg/mL and crystal screening was 
performed using solutions from Hampton Research. Significant crystal growth was 
noticed for all of the following screens: PEG/Ion (HR2-126), PEG/Ion2 (HR2-098), 
PEGRx 1 (HR2-082), PEGRx 2(HR2-084), Index 1-48(HR2-144), and Index 49-96(HR2-
144).  The most prominent crystal growth appeared in solutions containing between 19-
23% PEG 3350 and various salts.  After crystal growth optimization, Ig58 crystals were 
grown in 0.3-0.5 M NaCl, 19-23% PEG 3350, for eight days via hanging-drop vapor 
diffusion. Crystals were harvested using MicroMeshes (MiTeGen, Ithica, NY) and cryo-
protected in 50% glycerol (v/v) prior to freezing in LN2. An initial 2.7 Å data set was 
collected using an Oxford Diffraction Gemini diffractometer and a rotating copper anode.  
Indexing and processing of these data were performed with iMosflm with a sigma cutoff 
of 230,31. Data was subsequently scaled and merged with the program Aimless32 within 
the CCP4 program suite33,34.  Detailed instructions on how to operate these programs are 
included in the appendix. Phasing of the Ig58 reflections data was solved in PHENIX by 
molecular replacement using PHASER-MR crystallographic software with PDB # 2YZ8 
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as the search model35,36. Autobuild was used to generate a starting structure that then 
underwent 76 iterative rounds of manual model building and refinement, performed with 
COOT and PHENIX Refine35,38. A subsequent higher resolution data set was collected at 
the Structural Biology Center beamline 19-ID-D at the Advanced Photon Source, 
Argonne National Laboratory to 2.411 Å. The final data set used to solve the structure 
was collected from two different crystals.  Indexing and processing of high-resolution 
data were performed with HKL2000 by integration of single crystal diffraction data from 
area detector with a sigma cutoff of 230. Data was subsequently scaled, merged, and 
phased as described above, with the previously determined lower resolution structure 
used for molecular replacement, with the lower resolution structure undergoing its own, 
completely different set of refinement. The structure then underwent 160 iterative rounds 
of manual model building, as described above.  Atomic coordinates and reflections of the 
X-ray structure have been deposited in the RCSB Data Bank under accession number 
4RSV. Statistics are presented in Table 1. 
NMR:  
 NMR experiments, completed by Logan Meyer, were completed in a manner 
similar to those in Rudloff and Wright 201539.  The protein was purified using a modified 
version of the purification scheme described previously. The final 20 structures were 
selected (from 200) based on lowest energy and were of high quality based on the 
statistical criteria listed in Table 2.  Chemical shifts for Ig58 have been deposited in 
BMRB under accession number 25308 and the 20 best structures in the PDB under 
accession number 2MWC. 
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Molecular Dynamics: 
 All MD simulations were performed using the YASARA 12.4.1 software 
package, the AMBER03 force field, and explicit solvent (with 150 mM NaCl) in a size 
65 x 65 x 65 Å3 box at 25 oC40. 
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Results 
 This project was originally aimed at studying data from two domains of obscurin: 
Ig58/59 and Ig1/2.  Most of this manuscript however, deals with data on Ig58/59.  While 
initial experiments of Ig1/2 were promising, another lab solved the crystal structure of 
titin M10 in complex with Ig1 of obscurin41, and low resolution SAXS data were not 
interpretable due to polydispersity within the sample. For SAXS analysis, it is critical that 
the experimental sample is completely monodisperse, meaning that the protein in solution 
is entirely pure and is in no way aggregated. The lack of monodispersity of our sample is 
most likely due to the fact that the purified solution sat for too long before analysis, 
giving the protein time to break down and aggregate.  
 To begin probing the molecular mechanism of why the Ig58 and Ig59 domains of 
obscurin are important in myocyte organization and how the mutant phenotype of 
ArgàGln at the eighth residue of Ig58 is implicated in the disease HCM, we solved the 
high-resolution structure of Ig58 using both X-ray crystallography and NMR 
spectroscopy. The work here deals specifically with the high-resolution X-ray structure, 
solved in conjunction with Kelly DuPont, and its correlation to the NMR structure 
previously solved by Logan Meyer. The X-ray structure was solved by molecular 
replacement to 2.41 Å and is shown below in Figure 7A. 
 
 
	   
22	  
 
 
Figure 7. A) X-ray structure of Ig58 solved to 2.41 Å resolution with an Rfree 
value of 0.28. B) X-ray structure with ‘hot’ colors representing areas of high B-
factors and ‘cool’ colors areas with low B-factors. C) Manual refinement of Ig58 at 
1.5 sigma in COOT. Final structure determined from merging two data sets from 
two crystals.  
 
 X-ray data showed that Ig58 folds into a typical Ig-like fold (Figure 7A).  This 
fold consists of six core beta strands and one peripheral beta strand arranged in a beta-
sandwich like fold, characterized by two opposing antiparallel beta sheets8. In 
crystallography, the degree of relative vibrational motion of specific regions of a protein 
are represented by values termed, B-factors, measured in Å2. Atoms that are well ordered 
within the structure and experience little vibrational motion have low B-factors, and 
atoms belonging to flexible regions have high B-factors23,24 (Figure 7B). Upon structural 
refinement of the X-ray structure of Ig58, areas with high B-factors were often the most 
difficult to fit to the data. Due to their lack of non-covalent interactions, the loops display 
the most elevated B-factors and appear in warmer colors in Figure 7B. The total B-factor 
value, giving a readout of the overall flexibility of the protein, as well as many other 
statistical parameters, are listed below in Table 1. The use of both NMR spectroscopy and 
X-ray crystallography as structural techniques can provide complementary structural 
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information, as the true structure of the protein in vivo may be slightly misrepresented by 
one of these two techniques alone. This misrepresentation can occur through crystal 
packing artifacts in X-ray structures, which can affect the positions of the disordered 
regions such as loops tremendously. Problems may also arise due to areas of high motion 
in NMR structures making it hard to resolve the positions of atoms that are close 
together. It is therefore complementary to have both of these high-resolution structures, 
for the purpose of structural validation. Recognizing these facts, here we present both the 
NMR and the X-ray structure of the Ig58 domain of obscurin. 
Table 1: Statistics of the X-ray structure of Ig58, at 2.41 Å resolution. 
Resolution range (Å) 37.64  - 2.411 (2.496  - 2.411) 
Space group                            P 61 2 2 
Unit cell       44.482 44.482 177 90 90 120 
Total reflections                      11201 (1170) 
Unique reflections                   4329 (347) 
Multiplicity (°) 3.2 (3.4) 
Completeness (%)                   95.84 (80.14) 
Mean I/sigma(I)    29.47 (3.11)  
Wilson B-factor (Å2)                        66.54 
R-merge                 0.03344 (0.3173) 
R-meas                         0.04104 
CC(1/2)                    0.995 (0.931) 
R-work                   0.2463 (0.3529) 
R-free                   0.2649 (0.3225) 
Protein residues 90 
RMS(bonds)                         0.020 
RMS(angles)                            2.08 
Ramachandran favored (%)     84.6 
Ramachandran allowed (%) 13.4 
Ramachandran outliers (%)   0.0 
Clashscoremolprobity 37.75 
Average B-factor (Å2)  81.40 
*Values in brackets refer to highest resolution shell (2.496  - 2.411)34 
  The Ig58 NMR ensemble generated by Meyer, L., includes greater than 14 
restraints per residue, with no distance constraint violations greater than 0.4 Å and a Q-
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factor of 0.27 (Table 2).  The NMR-based structures agree well with each other, with a 
backbone RMSD of 0.471 Å for the 20 best structures (Figure 8A). 
Table 2:  NMR-derived restraints and statistics of 20 NMR structures. 
                 <20>  best 
rmsd from distance constraints (Å)1 
total  (1270)       0.027 ± 0.002  0.026 
intraresidue (276)      0.005 ± 0.004  0.005 
sequential ( |i – j| = 1)  (345)    0.015 ± 0.004  0.012 
medium range ( 1 < |i – j| ≤ 1)  (109)   0.048 ± 0.007  0.045 
long range ( |i – j| = 1)  (472)    0.029 ± 0.003  0.029 
hydrogen bonds  (68)     0.049 ± 0.008  0.053 
rmsd from exptl dihedral constraints (°) 
Φ,Ψ  (169)       0.463 ± 0.142  0.690 
rmsd from dipolar coupling restraints (Hz) 
DNH  (82)       0.74 ± 0.03  0.74 
rmsd from exptl 13C chemical shifts 
 13Ca (ppm)       1.34 ± 0.23  1.53 
 13Cb (ppm)       1.78 ± 0.19  1.73 
rmsd from idealized geometry 
 bonds (Å)       0.004 ± 0.001  0.004 
 angles  (°)       0.691 ± 0.020  0.668 
 impropers  (°)       0.618 ± 0.026  0.627 
Lennard-Jones potential energy (kcal/mol)2   -350 ± 12  -340 
Q-value 3        0.27 ± 0.04  0.24 
% most favorable region in the Ramachandran plot 4  70.6 ± 2.9  72.2 
all backbone atoms (3-92)                  0.471 ± 0.075  0.340 
all heavy atoms (3-92)              1.088 ± 0.081  1.070 
                                     1	  None of the 20 structures has a distance violation > 0.4 Å or a dihedral angle violation of > 5°. The 2	  Lennard-­‐Jones	  van	  der	  Waals	  energies	  were	  calculated	  using	  CHARMm	  parameters	  and	  were	  not	  used	  in	  any	  stage	  of	  the	  structure	  determination	  3	  Q-­‐values	  were	  determined	  by	  randomly	  removing	  10%	  of	  all	  RDC	  values.	  To	  ensure	  accuracy,	  an	  ensemble	  of	  structures	  with	  a	  second	  randomly	  removed	  subset	  of	  RDCs	  was	  also	  run.	  The	  Q-­‐value	  of	  this	  second	  set	  was	  similar	  to	  the	  first.	  4	  PROCHECK was utilized to generate the Ramachandran plot 
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 The NMR and X-ray structures are similar (heavy atom RMSD = 1.4 Å), with 
regions of the greatest difference in the B-C loop and the D-E loop (Figure 8B).  These 
are long loops, and display slightly elevated B-factors in the X-ray structure and fewer-
than-normal distance restraints in the solution ensemble. Thus, these slight structural 
differences are likely a function of local protein dynamics. The analysis of both of these 
high-resolution structures makes it possible to understand the molecular mechanism of 
how mutation to Ig58 leads to disease. 
 
 
 
 
 
 
 
 
 
Figure 8. A) 20 best NMR structures from the fully assigned Ig58 construct at 20 
mM Tris, 50 mM NaCl, 350 mM azide, 10% D2O, and pH 7.5 at 25° C. B) Overlay 
of X-Ray (purple) and NMR (gold) structures.  
  
 The 8th residue of Ig58 corresponds to Arg4344 of full-length human obscurin-a, 
and an ArgàGln mutation at this site has been linked to hypertrophic cardiomyopathy10, 
as previously stated. An Ig58 construct containing the ArgàGln mutation resulted in 
B 
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only minor changes in the HSQC spectrum, indicating that this mutant version remains 
similarly folded (Figure 9). The chemical shift changes between the wild type and mutant 
Ig58 were plotted based on standard deviation and are unique for each residue, 
represented in Figure 8. Projecting the resulting chemical shift changes onto the high-
resolution NMR structure shows that adjacent residues to the mutation display significant 
chemical shift perturbations (Figure 9).  
 
 
 
 
 
 
Figure 9. Ig58 construct containing the ArgàGln mutation resulting in minor 
changes in the HSQC spectrum. Projecting the resulting chemical shift changes 
onto the high-resolution structure shows that adjacent residues to the mutation 
(purple) display significant (>2x st. dev. for yellow and >3x st. dev. for red) 
chemical shift perturbations.  
 
Several residues on neighboring β-strands are also in different molecular environments 
(Figure 9).  These include residue Glu24, Gln26, Leu27, Ser28, Gln29, Glu56, and Gly81 
(Ig58 numbering).  Close inspection of the Ig58 electron density map reveals a series of 
charge-charge interactions between residues Gln26-Arg8, Arg8-Glu24, Glu24-Arg60, 
and conceivably between Arg60-Glu56 (Figure 10). The electron density, represented by 
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the black mesh in Figure 10, is actual crystallographic data. The location of the mesh 
indicates that, within the crystal, the residues at these positions are in close proximity. At 
many points the mesh is continuous between residues, and is evidence of the strength of 
the interaction between charge-charge pairs. 
 
 
 
 
 
 
 
 
Figure 10. Ig58 electron density map revealing a series of charge-charge 
interactions between residues Gln26-Arg8 (pink), Arg8-Glu24 (blue), Glu24-
Arg60 (black).  
 
Such charge-charge pairs could explain the long-range influence of the ArgàGln 
mutation on the chemical shifts.  Molecular dynamics simulations of the Ig58 structure, 
run by Berndsen, C., reveal that Arg8-Glu24, Arg8-Gln26, and Glu24-Arg60 all can exist 
in stable (>10 ns) interactions (Figure 11), and that these electrostatic bonds stabilize and 
shape a significant part of the Ig58 surface. Each trace of Figure 11 corresponds to one of 
the charge-charge interactions between two residues of Figure 10. The large, irregular 
peaks at the beginning, from 0 to 5 nanoseconds, are indicative of an equilibration period. 
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The flatness of the lines after that point indicates that the distances between these 
residues does not change and that these interactions are stable. 
 
 
 
 
 
 
 
 
Figure 11. Simulation of Ig58 in explicit solvent at 310 K and 100 mM NaCl, run 
by Berndsen, C.  Each trace represents the distances between two adjacent 
resides involved in a charge-charge interaction with colors corresponding to the 
distance measurements between residues of Figure 9.  
 
These three non-covalent interactions display long-lived charge-charge conformations, 
suggesting that all three contribute to the surface topology of this Ig58 face (Figure 10). 
Thus, while the Arg8Gln mutation may affect target binding through direct ablation of a 
protein-target coulombic interaction, it is equally feasible that this mutation disrupts 
target binding more generally by altering the overall target binding site topology or 
dynamics. 
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Discussion 
 The significance of solving the structure of Ig58 lies in the fact that this particular 
domain is the only region of obscurin that has both a known binding partner12 and a 
pathological mutation10. Therefore, the structural effects of the mutation adopt a more 
significant context when linked with the domain’s function, in this case, target protein 
binding. Analysis of the arrangement of residues provides strong insights into the effects 
of the mutation on the local and global structure, and consequently function, since 
structure dictates function. After obtaining information about the domain’s structure and 
function, we can begin to understand how the mutation in Ig58 effects myocyte function 
and how this is related to disease. 
 While more work must be done in order to make any claims about how this 
mutation is linked to HCM, it does seem possible that this mutation is responsible for the 
disease due to interference between obscurin-titin binding. Without obscurin and titin 
linked together as they would be in a wild-type cell, there could be moderate to severe 
cytoskeletal dysfunction42. Abrogation of this interaction seems to weaken the myofibril 
cytoskeleton. The Arg8Gln mutation to Ig58 does not appear to be a major weakening 
event, as the cytoskeleton remains in tact and only mildly dysfunctional. But the model is 
that like a hole in a wicker basket, over time it causes the rest of the cytoskeletal web to 
have to overcompensate, leading to thicker cardiomyocytes, and ultimately to HCM. 
Mutations to obscurin binding partners have also been linked to disease such as 
multiple mutations to the M10 domain of titin, which normally binds to Ig1 of obscurin39. 
These mutations have been linked to limb-girdle and tibial muscular dystrophy41, 
although the effects of the mutations on the protein structure and function have not been 
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fully characterized. It may be the case that a perturbed binding interface, similar to that of 
the ArgàGln obscurin Ig58 mutant, is also what is responsible for the diseases linked to 
other cytoskeletal proteins.   
It is perhaps surprising that a one-residue mutation on the surface of a single Ig-
like domain could lead to disease, especially since the overall conformation of the 
domain is largely maintained in spite of the mutation.  When the Arg8Gln mutation is 
introduced into Ig58, the domain maintains its fold, and in fact is only slightly distorted 
from the original structure based on chemical shift changes.  Structural analysis suggests 
that this mutation disrupts a moderately large network of electrostatic interactions on the 
Ig58 surface.  If charge-charge network is the titin binding site, as is postulated, then this 
mutation not only perturbs a potential inter-protein charge-charge interaction, but also 
changes the side-chain orientation of many nearby residues.  We also note that while Ig58 
was relatively easy to crystalize, the Arg8Gln mutation has still not been crystallized, 
despite repeated efforts.  The Arg8Gln mutation is not predicted to directly perturb any 
crystal packing interactions in the original Ig58 space group, and thus it is tempting to 
speculate that the Arg8Gln construct is more difficult to crystallize due to an increase in 
surface entropy43.  This parameter could then adversely affect target binding, leading to 
disease. 
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Conclusions 
Significant structural information complementing the NMR work of Meyer, L. was 
obtained through X-ray crystallography and molecular dynamics. There is strong 
evidence that the Arg8Gln mutation disrupts a tight, multi-residue charge interface on the 
surface of Ig58, and also has some non-local effects on structure. The mutation of 
Arg8Gln at residue number 8 of this structure may be causing cytoskeletal dysfunction 
and may ultimately be responsible for HCM due to ablated binding between obscurin and 
titin however, more work must be done in order to definitively prove that there is a direct 
correlation between the mutation and the disease. 
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Appendix 
 
Solving a Crystal Structure  
HKL Tutorial (Indexing) 
Written with Kelly DuPont  
 
HKL2000, Phenix, and Coot Tutorial 
 
HKL Steps: 
 
Step 0: Open HKL2000 
Open a terminal window, go all the way up in directories. Then go through ‘usr’ to ‘local’ 
to ‘bin.’ 
 
Step 1: Load Data 
Once HKL2000 has opened fully, look under the space titled ‘directory tree’ and click on 
‘berndsce,’ ‘Desktop,’ ‘APS4102014,’ then on the data folder you will be working on (eg. 
‘JMU113’ or ‘JMU211’).  
 
Designate your input folder, which is the data folder you just chose. This is where HKL 
will scan for data files. Create or assign where the output files will go and click ‘load data 
sets.’ To create a new folder, click ‘Create Directory’ and type the name.  
 
Click ‘Load Data Sets.’ You will choose the file with ‘data’ in the name, and NOT with 
‘scan’ in the name. Once this has opened, record your wavelength and frame width. 
Then, click on the tab entitled ‘Index.’ 
 
Step 2: Indexing 
Click on ‘fit basic’ and make sure that there are exactly 6 red boxes. Set resolution 
maximum to ‘corner’ if you think there is data that was not included and to ‘edge’ if you 
only want to go to the user set boundaries of the original data. For Synchrotron data, 
‘corner’ is more appropriate. The minimum resolution should be 50.00. Click on ‘Peak 
Sear,’ then, in the new window that appears, click on ‘Peak Search,’ and minimize the 
random peaks. This will usually involve lessening your peaks until they fall within the 
range 300-800. Record the number of peaks. Once this is done, click ‘OK’ then ‘Index.’ 
 
Step 3: Choosing a Space Group 
When the window appears for you to choose a space group, choose the group that has 
the highest symmetry with the lowest percent (usually it is green and closest to the 
top). Then click ‘Apply and Close.’ 
 
Step 4: Refining 
Your χ2 values should be less than 2. Click ‘Refine’ and continue to refine until your χ2 
values level out (are constant). At this time, the ‘Integrate’ button should be green 
(ideally).  If it is, press it. 
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If not, click ‘Fit All’ then ‘Refine’ again until the χ2 values level out. You may also need to 
change you space group, the values of which will have change due to your refining. 
Click ‘Bravais Lattice’ to open up your space group options. Again, choose the one with 
the most symmetry. If you do change your space group, you will need to refine again. 
Record the space group at the top of this screen. ‘Integrate’ should be green now, so 
press it.  
 
Step 5: Integrate 
Your mosaicity value should be less than 1. Record both it and your resolution range. 
Ideally, the graph on the left should look like one downward slope while the graph on 
the right should be fairly constant. Record your positional, partiality, X- χ2, Y- χ2, and χ2 
values. 
 
Step 6: Scale 
Click on the ‘Scale’ tab at the top and make sure your space group matches with the one 
you previously chose. Make sure that the box next to ‘Small Slippage, Imperfect 
Goniostat’ is red. Click ‘Fix B’ and make sure that ‘Write Rejection File’ is red also. Then 
click ‘Scale Sets,’ which should be green.  
 
Pay close attention to the graphs titled Completeness vs. Resolution and I/Sigma and 
CC1/2 vs. Resolution. These will aid you in determining the minimum value of your 
resolution. On the Completeness vs. Resolution graph, move your cursor to where the 
blue line begins to drop and remember this number. Scroll down to the CC1/2 vs. 
Resolution graph and move your cursor along the grey limit to where the grey meets the 
blue. This number should match up fairly decently with the number from before. 
However, to be more accurate, click on the ‘Show Log File’ button at the bottom and 
scroll down on the window that opens to the bottom. Compare the values in the 
Average I column to those in the Average error column and record the Shell lower limit 
for the line in which the Average I is approximately 2 times that of the Average error. 
This will be the minimum value of your resolution. Hit ‘Close’ on this window when done, 
set your minimum resolution, and the maximum for 50. 
 
Click ‘Delete Rejection File’ then ‘Scale Sets.’ 
 
Record a, b, c and alpha, beta, gamma. 
 
Your output file will have the name output.sca and will be wherever you specified it to 
go in the ‘Data’ tab. This is what you will use in CCP4. 
 
CCP4 Steps: 
 
Step 0: Opening CCP4 
From the Finder, go to ‘Applications,’ then ‘ccp4-6.4.0’ and ‘ccp4.’ (If it is not already 
down on the tabs, which it should be) 
 
Step 1: Running CCP4 
On the right side of the screen there is a program list. Under ‘Data Reduction and 
Analysis,’ click ‘Symmetry, Scale, and Merge (Aimless).’  
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In the window that pops up, make sure that ‘Option to skip scaling & just merge’ is 
black. Also, make sure the FreeR column has 0.05 in the blank and that ‘Copy FreeR 
from another file’ is grey. Change the Input reflection file type to ‘Scalepack file’ and 
choose your input/output destinations. SCA #1 is your input. You must input the 
‘output.sca’ file, NOT the ‘scalepack.sca’ file. 
 
If there are 2 input files, click ‘Add File’ and then browse to find that second file. This 
will merge both and output a single .mtz file for you to use. 
 
HKLOUT is where you type/choose the output destination. When choosing your output 
destination, you will have to name the file. To do this, choose the folder destination, 
click ‘OK’ and then add to the blank a /_____.mtz where the ____ is the desired file 
name. Then click ‘Run’ and ‘Run Now.’ 
 
If the process is finished quickly, chances are that you did something wrong. It should 
at least take a few seconds. 
 
Phenix Steps: 
 
Step 0: Creating a Folder for Data Collect in Phenix  
Create a folder on the phenix home desktop and name it something related to your 
project. This new folder will be where all of the output files will be directed to from 
Phenix and Coot.  
 
You can create subfolders for the preliminary data that you will need throughout the 
process of solving a crystal structure. This may include the sequence file for your protein 
as well as the .mtz file created from Indexing.   
 
 
Step 1: Creating a Reflection File 
To create a reflections file, open Phenix and create a new project ID. The following 
window will open.  
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Open the ‘Reflection Tools’ tab on the right hand side of the window. Then select the 
‘Reflection file editor’ and the following window will open.  
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Insert your short.mtz file created from HKL. This .mtz file will be used to create 
reflections of your protein structure. When you have added the .mtz file, a list of input 
arrays will pop-up in the section labeled All input arrays. 
 
Hit the copy all arrays button below the selection. This command will copy all file to the 
output arrays. Delete the files with the data type of integer.  
 
Then open the output options tab. The window should look as follows.  
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Make sure that Generate R-free flags if not already present is checked.   
 
Also check that the Fraction of Reflections in test set is at 0.1.  
 
Check to make sure the space group is correct. 
 
The rest of the output options will fill in automatically 
 
Make sure the output file is directed to the correct location  
 
Run the Reflection file editor. After the program is done, a reflections.mtz file will be 
added to the output location. Confirm the reflections.mtz file is in the correct location 
before opening the Xtriage tab on the home page of phenix.  
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Step 2: Xtriage_2 
Select the Xtriage option under Reflection tools on the Phenix home screen 
 
 
 
Once the xtriage program is open, find the reflections.mtz that was just generated from 
the reflection file editor.  
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Make sure the output directory is going to the correct folder. The purpose of preforming 
the xtriage program is to check the quality of data via checking the space groups, unit 
cell, and resolution.  
 
The output file is created in a folder called Xtiage_2. This will be found in the phenix 
folder that you created on the desktop.  
 
 
Step 3: Models and Templates for Molecular Replacement 
To obtain templates for generating an electron density map use Basic Local Alignment 
Search Tool (BLAST). Go to the website: blast.ncbi.nlm.nih.gov/Blast.cgi. Once on this 
site, go to the protein blast found under the heading Basic BLAST.    
 
The protein blast web page would look as follows.  
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On this screen, insert the sequence of the protein of interest into the large empty box at 
the top of the screen. Next select Protein Data Bank under the Database dropdown 
menu. Then click the BLAST button at the bottom of the screen.  
 
On this preceding screen there will be some statistics at the top that show how well your 
protein sequence matches those in the .pdb 
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At the bottom there will be a long list of solved structures of similar proteins. Each of the 
solved structures will have a percent sequence identity listed next to the four-character 
name for that particular structure. You want to have the highest percent sequence 
identity for your sequence meaning it could be 35% or greater. Once you choose a 
solved structure (or a few solved structures), you can preform molecular replacement. 
The higher the percent identity, the better your structure will be in the end because you 
will not have to build as much into the structure, which may lead to worse Rwork and Rfree 
values. If there are no solved structures that are similar to your protein sequence, then 
it may be useful to create poly-alanine models or truncated loop models. These can be 
used in molecular replacement to help...     
 
Once you have chosen the PDB structure that you want to use, go to rcsb.org to obtain 
the PDB file.  
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Here is where you select to download as a .pdb file  
 
Right next to the ascension number 
Under the tab for Model tools on the phenix home page, you will find a sub heading for 
PDB tools.  
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Enter into PDB Tools. 
 
Add the original .pdb for you protein. In this case it was 58model.pdb 
 
 
The output file will be directed to the folder that you created on the desktop. 
	   
48	  
 
 
 
Under the options tab in PDB Tools, select truncate to poly-Ala 
Then press run on the top of the tool bar 
 
 
To create the deleted loops model, open the original .pdb file in the program COOT. The 
delete icon on the right side on the figure below will pull up the choices in the secondary 
window for deleting an item in COOT. Choose the residue/monomer option. Then use 
the curser to click on the carbonyl carbon of the backbone. This will delete the backbone 
and the side chain of the amino acid in the loop.   
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It is difficult to see what secondary structure the amino acids are in within COOT, so use 
PyMOL to view the cartoon 
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Show the protein as a cartoon so that it is easy to see what is a loop and what is not. A 
loop is a turn between a secondary structure or in a random coil.   
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Step 4: Phaser-MR 
 
 
 
There are multiple programs within the molecular replacement tab on the home screen 
of Phenix. We advise that you begin using Phaser-MR.  
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After selecting Phaser-MR insert your reflections file into the Data file input bar under 
the input and general options tab. Also, select the correct output directory [your phenix 
(your name) folder] and make sure that the space group is correct.  
 
 
Next click the ensembles tab and add the file of one of your models or templates. Give 
them a title in the space labeled model ID. You can add multiple ensembles for 
molecular replacement to use by clicking the add pdb ensembles button at the bottom 
of the window. 
After you have added an ensemble click change variance and depending on whether it 
was a template or a model, enter the percent sequence identity or an RMSD of 2, 
respectively.  
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After you have added the desired amount of ensembles, click the composition tab and 
enter your sequence after choosing sequence string in the drop down menu of the 
Specify composition as: option. 
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Click the Search Procedure tab and under search method, select full. Also check the 
boxes of each ensemble you wish to use in the Model IDs: box. 
 
 
For each new run of molecular replacement, we recommend deleting ensembles entirely 
rather than simply unchecking them in the Model IDs: box if you wish to not use that 
particular ensemble.  
 
 
Now click the run icon. This should take a while to run. When the run is complete you 
will see a window similar to this. 
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Here you are looking for an LLG score that is as high as possible. My cohort and I were 
able to obtain values between 25 and 60, but the higher the better. You also want a TFZ 
score of 5 or very close to it.  
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Step 5: Autobuild
 
The next step in the process is to do autobuild on the results from Phaser-MR. If you are 
not already in Phaser-MR then you can find the autobuild program under the model 
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build tab on the home page on PHENIX. 
 
To run autobuild you need to have the following finals: 
 the sequence of your protein. (it should be a .txt file)  
 the original reflections file for your protein (.mtz) 
 the .mtz from the phaser run (the initial map in .mtz file) 
 the .pdb file from phaser (starting model) 
 
 
Before you move to the other options make sure the output directory is the correct place 
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Under the Other Options tab at the top of the screen, you need to fill the necessary 
refinement options. Most of the time you will want to include input model, build outside 
the model, refine model during building, refine input model before rebuilding. 
Depending on how many cycles you want to perform for the autobuild, the number of 
refinement cycles will change. This goes for max. iterative build cycles and max. 
iterative rebuild cycles as well. Usually the refinement cycles is 3, the build cycles is 6 
and the rebuild cycles is 15.  
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after the autobuild run is complete, you will see this screen under the status tab at the 
top. The goal here is to have a low R (~0.2) and a low R-free (~0.2). The R-free will 
always be above the R value, but you want to get the R-value and the R-free value 
within 0.05 of each other. The closer the model-map correction is to 1.0 the better. This 
indicates that the model produced from autobuild is close to the density map from the 
diffractions. The closer you are to 1.0 the less you have to manual build in COOT.  
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The summary tab shows you the output files that came from the autobuild run. From 
this page you can Run phenix.refine on the results that can out of the autobuild. 
Refinement will try to get the R-work and R-free closer together and closer to 0.2.  
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The model-building tab shows you the best R-work and R-free values that came from 
the autobuild.  
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The structure status tab will show how much of the structure has been identified for 
your protein. In this case there is a large portion missing from the middle of the protein 
sequence. This means that you will either have to go forward with this structure and run 
the phenix.refine and then manually build in that portion of the protein sequence in 
COOT or you can keep performing autobuilds until the structure gets better.  
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Step 6: phenix.refine
 
For phenix.refine you need two files in the file path. One needs to be the original 
reflections.mtz file and the other needs to be the .pdb file from the autobuild or the .pdb 
that you would like to refine. 
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Usually when you run phenix.refine the refinement setting are as follows:  
The strategy usually has the XYZ coordinates checked off, as well as real-space, rigid 
body, and individual B-factors 
The targets and weighing usually has NCS restraints, checked off as well as secondary 
structure restraints  
The other options usually has automatically correct N/Q/H errors 
 
 
HOWEVER, these do not always need to be checked off. For more information on what 
needs to be checked off, click on the question mark to read more about each of the 
options on this tab. You will learn what each parameter will do during the refinement. 
This will allow you to pick and choose what restraints or parameters to use when 
performing a refinement on your structure.   
	   
65	  
 
 
 
Before performing the refinement on your protein, make sure the results are being 
placed in the correct location.  
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Step 7: Manual Build in Coot
 
For more information on how to manually build in COOT, please refer to the COOT 
SECTION. 
 
 
 
Step 8: Comprehensive Validation 
Once you have a good looking structure from performing the manual build in COOT, you 
need to confirm that the structure looks OKAY. This means the R-work and R-free are 
within 0.05 of each other and they are near 0.2. To see what the R-work and R-free 
values are you need to run a comprehensive validation.  
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The comprehensive validation program is under the validation tab on the right hand side 
on the home page.  
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To run the validation program you need the following files: 
 the .pdb file that you want to validate 
 the original reflections.mtz file 
 the starting sequence file (.dat or .fasta) 
Also make sure the output files are going to the correct location/  
Once you have all the requirements for running the comprehensive validation program 
click RUN on the top bar.  
 
 
The results from the comprehensive validation will several important tabs to look at. The 
model and data tab will tell you about the R-work, R-free, RMS (bonds), RMS (angles) 
and the average B-factor. These are important to note especially the R-work and R-free 
because once they are close to 0.2 and within 0.05 of each other then you can run 
MolProbity on your structure. 
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The comprehensive validation will give you a summary from MolProbity but this is not 
good enough. You need to go on to the MolProbity website and run your structure 
through those programs.  
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Step 9: MolProbity http://molprobity.biochem.duke.edu/ 
ONLY do MolProbity when the R-work and R-free are close to 0.2 and within 0.05 of 
each other. If they are not within this range, then repeat the refinement (change the 
parameters if needed), then the manual build, and the comprehensive validation.  
 
For the MolProbity use the Evaluate X-ray structure under the Walk-thrus & tutorials. 
FOLLOW the instructions.  
If MolProbity says the structure is not good, then repeat the refinement step, along with 
the manual build in COOT and the comprehensive validation.  
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COOT SECTION: 
The figure below shows the electron density map for the protein. You need to make the 
sequence fit into the blue or green parts of the map. To do this follow the steps provide 
below. 
 
 
Step 0: Opening a Structure in Coot 
Click on ‘Open Coords…’ and select the .pdb file you received in the above steps. It will 
probably either be in an Xtriage folder or a Refine folder. You can also do this by clicking 
on ‘File’ then ‘Open Coordinates’ and selecting your .pdb file. This will open the chain of 
amino acids. 
 
You will then need to open up the electron density map. To do this, click on ‘File,’ then 
‘Auto Open .mtz’ and select the .mtz file that does NOT contain data in the name. 
 
Go to ‘Draw,’ then ‘Cell and Symmetry,’ ‘Yes,’ ‘Show,’ and ‘Apply’ to show the unit cells. 
 
Step 1: Basic Coot 
Right clicking and scrolling will allow you to zoom in and out of your structure. 
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Left scrolling will allow you to change how much electron density it shown. The 
numerical value will be displayed at the top of the structure picture. You should operate 
within the 1.5-2 range of these values. 
 
Left clicking on an amino acid will label it. To remove labels, go to ‘Measures,’ ‘Distances 
and Angles’ and click ‘Clear All Atom Labels.’ 
 
Left clicking and dragging will allow you to rotate the x-, y-, and z-axes around the 
center of your screen, which is represented by a pink square in the center of Coot. 
 
Holding down the control button on your keyboard while left clicking and dragging will 
allow you to move the center of your screen. 
 
 
When you are manually fitting the sequence into the density map, you want to get the 
sequence into the blue or green density as shown above. When there is red density, this 
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means that the sequence is not favorable to be in that area. You want to AVOID the red 
density*. The blue density is the occupied area that is acceptable.  
 
*When there is red density within your blue density, to use Dr. Berndsen’s words, “cry.” 
There is not much you can do here except use the ‘Real Space Refine Zone’ feature to 
move it out of the way as best as possible. This feature will auto fit your amino acid to 
the electron density map. 
 
Step 2: Navigating the Structure 
 
In able to move from amino acid to amino acid, select the ‘Go To Atom’ under the ‘Draw’ 
pulldown menu. This will allow you to move throughout the sequence one amino acid to 
the next. If there is more than one chain, it may be necessary to designate which one 
you want to navigate through. 
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The ‘Go To Atom’ screen looks like the figure above. You can move forward in the chain 
by clicking “Next Residue”. To move backward click on “Previous Residue.” 
 
An easier way to do this is to go to ‘Draw’ then ‘Sequence View’ and your .pdb file. This 
will display the entire chain in a window. Moving this window to the side will allow a 
quick jump from amino acid to amino acid. Clicking on the desired amino acid number 
will place you at that spot. 
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Step 3: Real Space Refine Zone 
The ‘Real Space Refine Zone’ may be the most helpful tool that Coot has to fit your 
structure. This will fit your amino acid to the electron density and allow you to position it 
the way you want. 
 
	   
76	  
 
 
The ‘Real Space Refine Zone’ will auto fit an area that you select. This will get the angles 
and bonds in optimal orientations for the sequence. To select one amino acid to refine, 
double click on some part of the amino acid. To select a larger region, single click on 
each side of the region. . Dragging an amino acid or region will allow you to finagle the 
region where you want it. It is easiest to grab the region by clicking and dragging from a 
“corner” or “bend” of the region. You will then have to accept or reject the refinement. 
Ideally, all of the categories below will be green. 
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Once the bonds and angles are in the optimal orientation press the accept button to 
keep the changes you made on the structure. Use discretion to determine whether or 
not an orientation is suitable. It is more important to match an amino acid to the given 
electron density than it is to have the orientation be optimal (have everything be green). 
 
There will be many green and blue regions surrounding the atom where waters, 
calcium, etc. will eventually go. Do not panic if you see these seemingly random regions 
go unfilled. 
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‘Regularize Zone’ is similar to ‘Real Space Refine Zone’ but may make more drastic 
changes. If you are having a lot of difficulty with a region, this may be good place to go 
as more of a last resort and may point you in the right direction. 
 
 
Step 4: Mutate and Auto Fit 
If you want to change an amino acid, use the ‘Mutate & Auto Fit’ button from the side 
menu that is shown above then select the amino acid you want to change it to. This can 
also be done with the ‘Simple Mutate…’ feature, but this will not fit the amino acid to 
your electron density. 
 
 
 
 
Step 5: Add Terminal Residue 
If there is an amino acid missing from the sequence you can add in an amino acid by 
using the ‘Add Terminal Residue’ button. After clicking it, click on the terminal carbon of 
your structure and then on ‘Accept’ in the window that pops up. Make sure that the 
added amino acid (it will be faded grey) is inside the electron density on your screen 
(you can move it by clicking on the grey amino acid and dragging it) before hitting 
‘Accept.’ 
 
	   
79	  
 
If the amino acid appears and is not connected to the rest of your chain, simply click 
‘Real Space Refine Zone’ and select an area containing the terminal residue and the 
newly added amino acid. The amino acid should then connect. 
 
Step 6: Ramachandran Plots 
 
To view the Ramachandran Plot, go to Validate, then Ramachandran Plot, then click on 
the .pdb file that you would like to view in the Ramachandran plot. You need to check 
the Ramachandran plot before you run the comprehensive validation because to have a 
good structure meaning that all the amino acids are in the pink regions on the 
Ramachandran plot. 
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As shown in the Ramachandran plot, all the residues need to be in the pink regions 
(ideally). If they are not you need to move the residue into the pink region, or at least 
the yellow region. When hovering your mouse over a square or triangle, it will show 
which amino acid that shape relates to. Those amino acids with squares have different 
Ramachandran favored regions than those with triangles.  
 
For a structure to be considered good, you need to have zero “Ramachandran outliers” 
and minimal “in allowed regions” (maximum in “favored” regions). Once you have 
checked this plot than you can go forward with validating your structure.  
 
A red shape means that the amino acid is a Ramachandran outlier, and should be fixed. 
A blue shape means that the amino acid is not an outlier, although it may or may not be 
in the favored region. A green shape represents the amino acid you currently have your 
screen’s focus on. Note that fixing an amino acid may involve moving the amino acids 
immediately before and after it. To fix or move an amino acid’s configuration, you can 
use the ‘Real Space Refine Zone,’ ‘Regularize Zone,’ or ‘Edit Backbone Torsions.’ All of 
these can be found on the right side of the Coot window, and ‘Edit Backbone Torsions’ 
may be the most helpful. 
 
Step 7: Edit Backbone Torsions 
Once in the ‘Edit Backbone Torsions’ window, you can either rotate from the peptide or 
the carbonyl. Note that this will change the Ramachandran plot for both the amino acid 
you are rotating and the one(s) around it. Try to get both shapes in the desired pink 
region, but make sure that they stay within the electron density. 
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Step 8: Check/Delete Waters 
When you have refined a structure using the ‘Update Waters’ feature in the refinement 
settings, the program will place waters in spots they do not actually belong. One way to 
check whether or not these are likely water spaces, click on ‘Validate,’ then on 
‘Check/Delete Waters’ and ‘OK.’ This will bring up a small window in which questionable 
waters are displayed. Check to see if the waters in these spots are too close or have too 
small of an electron density to constitute true waters. Note that there may be more 
incorrect waters than those in the questionable water window and that not all of the 
questionable waters may be incorrect. Use your best abilities to discern whether or not 
there should be waters in each place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   
82	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
